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Background: Scavenger receptor A (SRA) is expressed predominantly in phagocytic cells playing an essential role in
the host immune defense against invading microorganisms. Our previous study reported the presence of SRA in a
soluble form in patients with infection of hepatitis B viruses (HBV). However, the association of soluble SRA with
stages of HBV infection and the immune response induced by HBV is not fully determined.
Methods: In this study, we detected soluble SRA in serum from 29 chronic hepatitis B (CHB) patients, 28 chronic
HBV carriers in the immune tolerant (IT) stage, 33 in the HBeAg-negative inactive carrier (IC) stage, and 22 healthy
controls (HCs), respectively. We further analyzed the correlation of detected soluble SRA to inflammation and serum
viral load. In addition, we investigated the regulatory role of soluble SRA in T cell activation, especially in CD8+ T
cell response to HBV peptide.
Results: We demonstrated that Median levels of serum soluble SRA in CHB and IT patients were significantly higher
than those of IC patients and HCs. Additionally, the concentrations of soluble SRA were negatively correlated with
alanine transaminase levels in CHB patients. We also found that serum concentration of SRA was decreased during
telbivudine treatment. Expressed SRA extracellular domain suppressed HBV core peptide-stimulated interferon-γ and
tumor necrosis factor-α production in CD8+ T cells, and it bound to T cells in a higher frequency in CHB patients
than in HCs. Furthermore, we observed that naïve human T cells stimulated by anti-CD3 and CD28 antibodies in
the presence of the recombinant SRA protein had reduced activation and proliferation.
Conclusion: In summary, we determined the level of soluble SRA in different stages of CHB patients. SRA might
inhibit T cell proliferation and activation as a soluble form. These results not only revealed a previously unknown
feature of soluble SRA in CHB patients but also provided broad understanding of SRA in T cell activation.
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Hepatitis B is a serious and potentially life-threatening
liver infection caused by the hepatitis B virus (HBV),
which has become a major global health problem. About
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unless otherwise stated.the virus, and more than 350 million have chronic
(long-term) infection [1]. Chronic infection with HBV
can lead to severe liver diseases including advanced fi-
brosis, cirrhosis, and hepatocellular carcinoma (HCC),
causing an estimated 600,000 deaths each year [2]. In pa-
tients with chronic HBV infection, there is a reduction
or functional exhaustion of HBV-specific CD4+ and
CD8+ T cell responses compared with responses from
individuals who succeed in resolving infection [3,4]. CD8+
T cells, the main effector cells in viral clearance of HBV,
produce an array of cytokines, among which interferon
gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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target cells [5,6]. Exhaustion of CD8+ T cells has been
demonstrated in patients with chronic HBV infection
[7]. Lopes et al. found pro-apoptotic protein Bcl2-
interacting mediator (Bim) was upregulated in HBV-
specific CD8+ T cells from patients with chronic infections
compared with resolved infections [8,9]. In addition, in-
creased expression of inhibitory molecules such as PD-1,
CTLA-4, and TIM-3 may contribute to dysfunction and
apoptosis of virus-specific CD8+ T cells [9-12]. Other ex-
trinsic factors in the liver microenvironment, such as im-
munosuppressive cytokines IL-10 and TGF-β can also
hamper the ability of T cells to expand and survive, thereby
attenuating anti-viral control [13]. Thus, blockade of the
inhibitory pathways could be a logical, reasonable
therapeutic strategy to rescue dysfunctional T cells and
would likely restore functional T cell response in
patients.
Scavenger receptor A (SRA, also called CD204) is
expressed primarily on phagocytic cells or antigen present-
ing cells (APCs), such as dendritic cells (DCs) and macro-
phages [14], as well as on liver sinusoidal endothelial cells
(LSECs) [15]. SRA has been studied extensively in the con-
text of atherosclerosis or cardiovascular diseases, where it
was identified initially as a major receptor for internaliza-
tion of modified lipoproteins [16]. SRA has also been
shown to function as an innate pattern recognition recep-
tor (PRR) capable of recognizing a broad spectrum of “self”
and “non-self” ligands, including modified or altered mole-
cules, pathogen-associated molecules, and endogenous
danger molecules such as stress proteins [14,17]. Studies
emerging from the field of tumor immunology showed
SRA functions as a suppressor of T-cell activation and anti-
tumor immunity [18,19]. SRA also suppresses CTL and
Th1 responses triggered by model antigen OVA with LPS
or monophosphoryl lipid A (MPL), a pathogen-associated
molecular pattern (PAMP) that engages the toll-likeTable 1 Clinical characteristics of subjects in cross sectional s
Group HC IT
No. of patients 22 28
Gender(M/F) 12/10 10/1
Age(year) 25.0 (22.2-33.8) 26.0
HBV-DNA(log10 copies/mL) n.d. 8.00
ALT(U/L) 14.5 (8.3-27.9) 26.0
HBsAg positive 0 28
Anti-HBs positive 16 0
HBeAg positive 0 28
Anti-HBe positive 0 0
Anti-HBc positive 0 28
Data are shown as median (10–90% percentile).
ALT, alanine aminotransferase; CHB, chronic hepatitis B; HC, healthy control; IC, inac
HBsAg, hepatitis B surface (HBs) antigen; HBeAg, hepatitis B e antigen; n.d., not detreceptor 4 (TLR4) signaling pathways [20,21]. It has been
reported that SRA is responsible for uptake of adenovirus
5 in macrophages [22]. However, little is known about the
role of SRA in the pathogenesis of chronic HBV infection
and the virus-induced T cell response.
Our previous study found increased serum levels of
soluble SRA in patients were associated with occur-
rence of chronic hepatitis B (CHB) infection [23]. In
the present study, we conducted a cross-sectional com-
parison of the levels of soluble SRA in subjects who
were either HBeAg-positive or HBeAg-negative, and we
evaluated the concentration of serum SRA in subjects
of telbivudine treatment. We analyzed the effect of
SRA on in vitro activation of HBV peptide-induced
CD8+ T cell or anti-CD3/CD28-induced T cell activa-
tion. In addition, we investigated the interaction be-
tween soluble SRA and T cells and the effect of SRA on
T cell priming. Our study revealed SRA negatively reg-
ulated HBV-induced CD8+ T cell responses in a soluble
form, which might represent a mechanism of T cell ex-
haustion in CHB patients.Results
Elevated levels of serum-soluble SRA in CHB patients
Our earlier observation of increased levels of soluble
SRA in mice with immune-mediated liver injury and
clinical hepatitis [23] prompted us to evaluate the asso-
ciation between stages of chronic HBV infection and
serum soluble SRA concentrations in this cross-
sectional study (Table 1). We evaluated the concentra-
tion of soluble SRA in serum from patients and HCs
using ELISA. Soluble SRA levels in CHB patients were
significantly higher than those in HCs and IC patients.
In contrast, there was no significant difference in sol-





(17.4-36.2) 27.0 (22.0-38.0) 33.0 (22.0-43.8)







tive carrier; IT, immune tolerant;
ermined.
Figure 1 Cross-sectional analysis of the soluble SRA level in patients with hepatitis B virus. (A) Comparison of serum soluble SRA concentrations
in healthy controls (HC) (n = 22), subjects in the immune tolerance (IT) (n = 28) and inactive carrier (IC) (n = 33) stages of a chronic HBV infection,
and patients with HBeAg-positive chronic hepatitis B (CHB) (n = 29). (B) The relationship of serum soluble SRA concentration with HBV DNA in
patients with HBV DNA above 1000 copies/mL (n = 48). (C) The relationship of serum soluble SRA concentration in CHB patients (n = 29) with
alanine transaminase (ALT) levels. (D) Serum SRA concentrations at baseline and at 12 and 24 weeks after starting telbivudine therapy in 6 patients with
HBeAg-positive chronic hepatitis B.
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HBV DNA load in patients with HBV DNA above 1000
copies/mL (n = 48), finding no significant correlation be-
tween the level of soluble SRA and plasma HBV DNA
load (Figure 1B). We next analyzed the correlation be-
tween serum SRA level and alanine aminotransferase
(ALT) level in the CHB patients (n = 29). In contrast to
the results for HBV DNA load, concentration of soluble
SRA was negatively correlated with ALT level (Figure 1C).Table 2 Clinical characteristics of the subjects with telbivudin
Treatment week
Variable 0
HBV-DNA(log10 copies/mL) 8.64 (6.84-9.18)
ALT(U/L) 63.0 (15.0-147.0)
TBil (μmol/L) 14.4 (5.5-14.9)
SRA(ng/mL) 10.4 (9.3-21.2)
Data are shown as median (10–90% percentile). TBil, total serum bilirubin.Additionally, the serum level of SRA was decreased signifi-
cantly after telbivudine treatment (Figure 1D and Table 2).
Extracellular domain of SRA suppressed HBV antigen-
induced CD8+ T cell response
To further observe if there is any potential effect of soluble
SRA on HBV-induced CD8+ T cell response in chronic
HBV infection, we prepared a recombinant extracellular
domain of the SRA protein (SRA-ECD) using the pETe therapy (n = 6)
12 24
5.06 (3.30-6.09) 3.86 (2.46-5.38)
31.0 (21.0-79.0) 29.0 (17.0-51.0)
14.8 (7.7-27.7) 18.4 (6.5-25.4)
16.19 (8.7-19.8) 7.6 (4.2-9.7)
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nous domain of SRA has been known to bind lipopolysac-
charide (LPS) [24], and the recombinant protein has
similar ligand-binding property as endogenous SRA as de-
termined by ELISA (Addtional file 1 Figure 1). SRA-ECD
protein significantly inhibited the production of cytokine
IFN-γ and TNF-α by CD8+ T cells stimulated with HBV-
specific peptides (Figure 2B and C). To rule out the possi-
bility that the suppressive effect might be artificially
derived from the expression system, we used a GST tag
expressed by the identical prokaryotic expression vector as
a negative control. We found that the expression system
itself had no effect on HBV antigen-induced CD8+ T cell
function (Figure 2B). Compared with the vehicle group
treated with HBV peptide stimulation at 0%, the reduction
of IFN-γ and TNF-α in the SRA-ECD protein-treated
group were statistically significant (Figure 2C).
We next assessed the occurrence of SRA binding to
T cells during the HBV-induced immune response. We
employed a biotinylated recombinant SRA-ECD pro-
tein to target a putative receptor on T cells, and found
SRA-ECD bound a subset of T cells (Figure 3A). Strik-
ingly, the percentage of positive T cells was signifi-
cantly higher in CHB patients than in healthy controls
(Figure 3B).Figure 2 SRA-ECD protein suppressed HBV antigen induced CD8+ T cell resp
expression system, then analyzed by SDS-PAGE and immunoblotting with ant
core peptides, and subjected to intracellular cytokine staining assays. The perc
calculated. Representative dot plots from three independent experiments are
unrelated protein control. The inhibited percentages were calculated and sumSRA-ECD protein inhibited T cell proliferation and
cytokine production
To evaluate the function of SRA on T cell receptor
(TCR)-mediated T cell activation and function, we stim-
ulated purified T cells from healthy controls with both
anti-CD3 and anti-CD28 antibodies in the absence or
presence of different doses of SRA-ECD recombinant
protein. As expected, SRA-ECD protein inhibited T cell
proliferation (Figure 4A) and cytokine (i.e., IL-2, IFN-γ
and IL-4) production (Figure 4B) in a dose-dependent
manner. In contrast, GST protein did not have any sup-
pressive effect on T cell activation, suggesting the speci-
ficity of inhibitory activity of SRA-ECD recombinant
protein for T cell priming and activation. To determine
whether the T cell suppression function of SRA is a result
of SRA-mediated T cell apoptosis or inhibition of T cell
activation, we evaluated T cell apoptosis using Annexin V
staining after 3 days of stimulation with anti-CD3 and
anti-CD28 antibodies stimulation in the presence or ab-
sence of recombinant SRA protein. The results showed no
difference between the groups treated with SRA-ECD pro-
tein versus GST protein (Additional file 1 Figure 2). The
intercellular staining of IFN-γ confirmed the suppressive
function of soluble SRA on T cell activation (Figure 4C).
We also found the inhibitory effect of soluble SRA on Tonses. (A) Recombinant SRA-ECD protein was prepared using the pET
i-SRA antibody. (B) PBMCs from CHB patients were stimulated with HBV
entages of HBV peptide-induced cytokine-producing CD8+ T cells were
shown. GST protein prepared by the same procedure was used as an
marized (C).
Figure 3 SRA-ECD protein binds to T cells from CHB patients more efficiently. Whole blood from healthy controls and CHB patients was analyzed
for SRA-ECD binding with antibodies for CD3 after red blood cell lysis (A). Summaries of 15 healthy controls and 28 CHB patients are shown (B).
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similar between CD4+ or CD8+ T-cell subsets (Figure 4D).
Furthermore, we measured the binding capacity of
SRA to naïve T cells or anti-CD3/CD28 stimulated T
cells. Stimulated T cells were strongly bound by SRA-
ECD protein compared with naïve T cells (Figure 4E).
SRA-ECD inhibition of T cell proliferation was IL-2-dependent
and involved in initiating TCR signal transduction
To further investigate whether the inhibition of T cell
activation by soluble SRA-ECD protein was the result of
a decrease in IL-2, we added a high concentration of ex-
ogenous IL-2 to the T cells treated with anti-CD3/CD28
co-stimulation in the presence or absence of SRA-ECD
protein. Complementary IL-2 could restore proliferation
of T cells in the presence of both SRA-ECD protein and
anti-CD3/CD28 (Figure 5A). No effect of exogenous IL-2
was observed in proliferation of T cells without stimula-
tion in absence or presence of SRA-ECD protein (data
not shown). Taken together, these results implied that
inhibition of T cell activation in the presence of SRA-ECD
protein might be due to reduced expression of IL-2.
We next tested whether soluble SRA might interfere
with early signaling events after TCR engagement. Con-
sidering that TCR signal transduction requires activation
of ZAP-70 protein tyrosine kinase for all downstream
signaling events [25], we evaluated the effect of SRA
protein on the ZAP-70 phosphorylation upon T cell acti-
vation. Western blot analysis showed that the presence
of SRA-ECD protein during initiation of TCR signal
transduction was associated with inhibition of phosphoryl-
ation of ZAP-70 (Figure 5B).
Discussion
We previously identified the presence of a high level of sol-
uble SRA in serum from patients with HBV infection [23].However, the mechanism underlying this phenomenon re-
mains unclear. The purpose of this study was to validate
our hypothesis that soluble SRA could negatively regulate
HBV-induced immune effector functions, thereby imped-
ing the host response towards HBV eradication. We first
conducted a cross-sectional study to investigate the associ-
ation between serum levels of soluble SRA and the clinical
status of subjects with HBV infection. We next demon-
strated the inhibitory effects of soluble SRA on HBV
peptide-induced CD8+ T cell responses and analyzed the
interaction between SRA and T cells. Our studies provided
a preliminary understanding of the involvement of soluble
SRA during HBV infection and its action in modulating
the antiviral immunity.
Few studies have previously examined the role of SRA in
viral infection and immunity; however, uptake and degrad-
ation of adenoviruses through SRA by macrophages has
been reported [22]. Here, we observed that serum SRA
levels in CHB patients were comparable to that in HBeAg-
positive immunotolerant patients, but were significantly
higher than those of the inactive carriers who had com-
pleted HBeAg seroconversion. It was previously reported
that functional responsiveness of circulating HBV-specific
CD8+ T cells was crucial for eliciting an HBeAg response
[26,27]. This raised the possibility that higher levels of
soluble SRA might be associated with suppression of
anti-viral CD8+ T cell responses, which could subse-
quently cause persistent HBV infection and failure of
HBeAg seroconversion while reducing SRA concentra-
tion in patients. This might favor restoration of anti-
HBV CD8+ T cell responses during anti-viral treatment.
Among patients with CHB, correlation between serum
ALT and soluble SRA levels implied that the serum
levels of SRA might be biologically related to the severity
of liver inflammation. This indicated that soluble SRA
might be an inflammatory biomarker upregulated in the
Figure 4 SRA-ECD protein inhibits T cell proliferation and cytokine production. (A, B) T cells purified from human PBMCs were stimulated with anti-CD3
(1 μg/mL) and anti-CD28 (1 μg/mL) antibodies in the presence of the indicated concentration of SRA-ECD protein for 72 hr. T cell proliferation was
assessed by FACS analysis of CD3+ T cells based on the dilution of CFSE intensity. Histograms are representative of two independent
experiments (A). Supernatants were collected after 48 h and assayed for IL-2, IFN-γ and IL-4 using ELISA (B). (C) Naïve T cells stimulated
with anti-CD3 and anti-CD28 antibodies for 72 hr. Then the cells were re-stimulated with anti-CD3 and anti-CD28 antibodies in the absence
(medium) or presence of different concentration of SRA-ECD protein for 6 hours and subjected to intracellular cytokine staining assays. The
percentages of IFN-γ-producing CD3+ T cells were calculated. Representative dot plots from two independent experiments are shown.
(D) CFSE-labeled naïve T cells were stimulated in plates coated with anti-CD3 anxd anti-CD28 antibodies in the absence or presence of
10 μg/mL of SRA-ECD protein. After 72 h, T cells were stained for CD3, CD4 and CD8 respectively. T-cell proliferation was assessed by FACS
analysis based on the dilution of CFSE intensity. Histograms are representative of three independent experiments. (E) Human PBMCs were
activated with anti-CD3 and anti-CD28 antibodies co-stimulation for 48 h, and cells with and without stimulation were analyzed for SRA-ECD binding
together with antibodies for CD3. Data are representative of three independent experiments.
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does not necessarily impact viral clearance. It should be
noted that telbivudine treatment can significantly decrease
the HBV DNA load in the CHB patients [28]. In our study,
we also found a decrease of serum SRA levels aftertelbivudine treatment. SRA protein might also participate
in the suppression of chronic viremia, which remains to
be investigated. Yla¨-Herttuala et al. derived soluble SRA-
containing medium from AAVsMSR-transduced rabbit
fibroblasts, and they found that the conditioned
Figure 5 Impaired T proliferation by SRA-ECD could be reverted by IL-2. (A) CFSE-labeled naïve T cells were stimulated with immobilized anti-CD3
(0.5 μg/mL) and anti-CD28 (0.5 μg/mL) antibodies or anti-CD3/28 plus SRA-ECD in the presence or absence of recombinant IL-2 (100 U/mL). After 72 h,
cells were stained for CD3, and proliferation and cell death induction was determined for CD3+ T cells. The data are representative of one experiment
among three independent experiments. (B) Purified T cells were activated on plates coated with anti-CD3 and anti-CD28 antibodies in the absence or
presence of SRA-ECD protein. Phosphorylation of ZAP-70 was determined by western blot analysis at different time points. GAPDH was used
as a loading control. Immunoblot bands were quantified by densitometry analysis using ImageJ software. The data are presented as ratio of
protein expression compared with GAPDH expression for each sample. The result presented is from one representative experiment among
two independent experiments. N.S. stands for not statistically significant.
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[29] and suppressed the THP-1 monocyte/macrophage
adhesion on OxLDL-activated endothelial cells [30].
These results indicated that soluble SRA might influ-
ence atherogenesis and the subsequent inflammatory
response. Indeed, there were a number of studies showing
a regulatory function for cell-surface SRA in the inflam-
matory response. Kobzik et al. reported that SRA sup-
pressed production of IL-12, a crucial regulatory cytokine
driving the Th1 response, in macrophages stimulated withCpG or LPS plus IFN-γ [31,32]. A previous study showing
that SRA−/− mice produced more IL-10 compared with
wild-type mice emphasized the involvement of SRA in the
anti-inflammatory response [33]. We speculated that
soluble SRA in circulation might limit the inflammatory re-
sponse inside liver the as it does in the peripheral system.
CD8+ T cell deletion experiments performed in HBV-
infected chimpanzees have provided strong support for
the concept that CD8+ T cells are the main cellular subset
responsible for viral clearance [6]. It has been reported
Chen et al. BMC Immunology  (2015) 16:29 Page 8 of 11that responses with a Th1 profile of cytokine produc-
tion by HBV-mediated CD4+ and CD8+ T cells were as-
sociated with a more favorable disease outcome [6,34].
Patients with chronic HBV infection have a weak or
undetectable virus-specific T-cell response [35,36]. A
growing body of evidence revealed the role of SRA in
suppressing antigen-specific CTL responses against tu-
mors [18]. The effect of SRA on CD8+ T cell responses
was also examined using the model antigen OVA. The
result showed that SRA−/− DCs were much more effective
than wild-type DCs in driving OT-I cell proliferation
in vitro [20]. In addition, we previously found that the per-
centage of IFN-γ-producing CD4+ T cells in SRA−/− mice
was significantly higher compared with those in WT mice
after vaccination with OVA immunogen [21]. We have
shown that soluble SRA protein suppressed HBV peptide-
induced CD8+ T cell response compared with an unrelated
control protein (GST). The data suggested the soluble form
of SRA, like its membrane-bound counterpart, exhibits a
direct suppressive effect on T cell response. Surprisingly, we
found that SRA protein also reduced the amount of IL-4
secretion upon T cell activation. IL-4 is the primary cyto-
kine implicated in the development of Th2-mediated re-
sponses, which is associated with allergy and asthma [37].
A previous study found that SRA deficient mice showed a
much more allergic inflammatory response compared to
the wild-type counterpart [38]. It is worthy to investigate
whether and how SRA regulates Th2 response during
asthma.
The SRA-ECD protein we prepared had higher effi-
ciency binding to T cells from patients with HBV infec-
tion than from healthy controls. Further study revealed
that SRA-ECD protein preferably interacted with acti-
vated T cells rather than naïve T cells. This indicated sol-
uble SRA might recognize unidentified receptors mainly
induced after T cell activation. TCR engagement by anti-
gens triggers a cascade of tyrosine phosphorylation of
signaling components, leading to the activation of mul-
tiple pathways, which ultimately induces T cell growth
factor (e.g. IL-2) gene expression. When the TCR inter-
acts with peptide antigen bound to a MHC complex
molecule on antigen presenting cells, the TCR co-
receptor CD4 or CD8 binds to the MHC complex, acti-
vating the co-receptor associated tyrosine kinase Lck,
which is brought into proximity of the CD3 complex
and phosphorylates tyrosines in the immunoreceptor
tyrosine-based activation motifs (ITAMs). When doubly
phosphorylated, ITAMs interact with the tandem SH2
domains of ZAP-70. Active ZAP-70 subsequently phos-
phorylates LAT and SLP-76, which recruit many other
signaling molecules and lead to T-cell activation, prolifera-
tion, and differentiation [25]. Subsequently, IL-2 binds its
receptors to promote activated T cell proliferation with nu-
cleotide synthesis through the PI3K/AKT pathway andmammalian target of rapamycin (mTOR)/p70S6K pathway.
Our study showed that the inhibitory effect of SRA-ECD
protein on T cell activation could be through an IL-2
dependent manner. SRA-ECD protein greatly reduced the
IL-2 production and addition of exogenous IL-2 restored
the proliferation of T cells treated with SRA-ECD protein.
These results demonstrated that soluble SRA could serve
as a negative regulator of T cell activation. However, it re-
mains to be determined how soluble SRA regulates the ini-
tiation of T cell signal transduction.
Conclusion
Taken together, increased soluble SRA expression in
patients with chronic HBV infection is important for de-
creasing T cell activation, and soluble SRA is involved in
inflammatory liver pathology. This study demonstrated
soluble SRA served as a negative regulator in T cell re-
sponses. Compared with recently identified co-inhibitory
molecules (e.g., PD-1, CTLA-4, TIM-3) present on T cells
[9-12], our research is focused on a host-derived inhibitory
molecule that is mainly expressed on myeloid cells or
present in a soluble form. Insightful understanding of the
negative regulation of SRA in inflammation and immunity
in HBV infection may provide new opportunities for
therapeutic intervention in CHB patients.
Methods
Human Subjects
Twenty-nine chronic hepatitis B (CHB) patients, 28
chronic HBV-infected patients in the immune tolerant (IT)
stage, 33 in the HBeAg-negative inactive carrier (IC) and
22 healthy controls (HC) were enrolled in the cross-
sectional study. CHB patients as well as IT and IC were di-
agnosed according to the described criteria [39]. Subjects
with previous antiviral therapy, co-infection of HIV or
other hepatitis virus, diabetes, severe systemic illness, regu-
lar alcohol over-consumption and hepatocellular carcin-
oma were excluded. Basic characteristics of the enrolled
subjects were summarized in Table 1.
Six CHB patients from a phase IV, multi-center, open-
label clinical trial of telbivudine (600 mg/d, n = 21, trial
number CLDT600ACN07T) were enrolled for longitu-
dinal study, and heparinized blood was taken at baseline,
12 and 24 weeks of telbivudine treatment (Table 2), re-
spectively. The study protocol was approved by the
Medical Ethical Committee of Nanfang Hospital of
Southern Medical University. Prior to the collection of
blood sample, the informed consent for participation in
the study was obtained from each participant or parent
if the participant is under 18 years of age.
Serological assays and HBV-DNA assays
Presence of HBsAg, HBeAg, anti-HBs, anti-HBc, anti-
HBe, anti-HCV, and anti-HDV was determined using
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North Chicago, IL, USA). The HBV-DNA level was
quantified using the Roche Diagnostics Cobas Taqman
48 (Meylan, France). The biochemical analyses were
conducted with an OLYMPUS AU5400 Full Automatic
Biochemical Analyzer (Olympus Corp., Tokyo, Japan).
ELISA Analysis of Soluble SRA
Soluble SRA levels in human serum samples were mea-
sured in duplicate using a commercial ELISA kit purchased
from Uscn Life Sciences (Wuhan, China).
Protein preparation
Recombinant extracellular domain of human SRA was
expressed in Escherichia coli using the pET expression
system (Novagen, Madison, WI, USA) and purified by
nickel-chelating resins (GE Healthcare, Piscataway, NJ,
USA) according to the protocols. The expressed protein
was determined by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) analysis and western
blot analysis using anti-human SRA antibody (Abcam,
Cambridge, MA, USA).
Cell surface and intracellular staining
Whole blood was incubated with FCM Lysing Solution
(Mutisciences, Hangzhou, China) for removal of red blood
cells, followed by staining with SRA-ECD protein biotinyl-
ated with Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL,
USA) and anti-CD3-APC (BD Biosciences, San Jose, CA,
USA) for flow cytometric analysis of binding of SRA-ECD
protein with T cells.
Intracellular cytokine staining (ICS) was performed as
previously described [40,41]. Briefly, freshly isolated PBMCs
from CHB patients and HLA-A2(+) PBMCs were selected
for stimulation by HBV core18-27 peptide (FLPSDFFPSV)
and 18-mer overlapping peptide pool covered C open
reading frame (1 μg/mL, GL Biochem, Shanghai,
China) plus anti-CD49d (1 μg/mL, BD Biosciences)
and anti-CD28 (1 μg/mL) for 10 days. Then the cells
were re-stimulated with 3 μg/mL of core18-27 and the
18-mer peptide pool for 1 hour, followed by incubated
with 1 mg/mL of brefeldin A (BD Biosciences) for an
additional 5 hours. After surface staining with anti-CD8-
APC (BD Biosciences), cells were fixed, permeabilized,
and stained with anti-IFN-γ-PE and anti-TNF-α-PECy7
(BD Biosciences) respectively according to the manufac-
turer’ s instructions. In this study, positive response was
defined as greater production of either IFN-γ or TNF-α by
core peptide-stimulated CD8+ T cells compared with
either culture medium-stimulated or HIV gag peptide-
stimulated CD8+ T cells. Patients with a positive CD8+ T
cell response were chosen for the T-cell suppression
assays. The percent inhibition was calculated by thefollowing formula: percentage of inhibition = [(normal
activity - inhibited activity)/(normal activity)] ×100%.
In Vitro T-Cell Stimulation
CellTrace 5(6)-carboxyfluorescein diacetate succinimidyl
ester (CFSE) (Molecular Probes, Eugene, OR, USA) la-
beled human T cells were plated at 2 × 105 cells/well in
1 μg/mL of anti-CD3 Abs (eBioscience, San Diego, CA,
USA)-coated plates in the presence of 0.5 μg/mL of anti-
CD28 Abs (eBioscience) with or without indicated con-
centrations of recombinant SRA-ECD protein. In some
case, 100 U/ml of IL-2 was added in the incubation. Prolif-
eration was analyzed using FACS based on the dilution of
fluorescence intensity. Supernatants were collected at
48 hours after the stimulation for cytokine assays using
commercial ELISA kit (eBioscience).
Western blot
Purified T cells were serum starved overnight in complete
medium supplemented with 0.5% FCS, and subsequently
activated on anti-CD3 antibodies (1 μg/ml) coated plates
in the presence of anti-CD28 antibodies (1 μg/ml) with or
without SRA-ECD protein (10 μg/ml). Activated cells were
lysed using RIPA buffer (50 mM Tris, 150 mM NaCl, and
1% Nonidet P-40, pH 7.4) and protein lysates were sub-
jected to western blot analysis with antibodies against
phospho-ZAP70, ZAP-70 (Cell Signaling Technology,
Danvers, MA, USA) or GAPDH (Thermo scientific Inc.,
Waltham, MA, USA).
Statistical analysis
Continuous data are expressed as either the median
(10th–90th percentile) or the mean ± SEM. Independent
samples t test, Mann–Whitney test or Chi square test
were used in group comparisons. Spearman’s rank order
correlation coefficient was used for correlation analysis.
All statistical analyses were based on two-tailed hypothesis
tests with a significance level of p < 0.05.
Additional file
Additional file 1: Supplement Figure 1. Recombinant SRA-ECD protein
binds with LPS. Supplement Figure 2. Recombinant SRA-ECD protein
does not induced T cell apoptosis during anti-CD3/CD28 stimulation.
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